Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc. (LBPH): 4 pipeline candidates · ~40 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
40.3 months
13% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for Longboard Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$27.9M
Quarterly Burn
$20.6M
Runway
40.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| Bexicaserin (LP352) | Phase 3 |
| LP352 | Phase 3 |
| LP352, bexicaserin | Phase 3 |
| LP659 | Phase 1 |
Frequently asked questions
How many drug candidates are in Longboard Pharmaceuticals, Inc.'s pipeline?
Longboard Pharmaceuticals, Inc. (LBPH) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Longboard Pharmaceuticals, Inc.'s lead drug candidate?
Longboard Pharmaceuticals, Inc.'s most advanced tracked candidate is Bexicaserin (LP352) (Phase 3) for Developmental and Epileptic Encephalopathy.
What is Longboard Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Longboard Pharmaceuticals, Inc. has approximately 40.3 months of cash runway.
Who is the CEO of Longboard Pharmaceuticals, Inc.?
Chief Executive Officer is the chief executive officer of Longboard Pharmaceuticals, Inc. (LBPH).
Get the full picture on Longboard Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.